Positive FDA Review on Optimer Pharmaceuticals’ (Nasdaq:OPTR) Fidaxomicin – CRWENewswire.com Stock Highlight

Apr 2nd, 2011

optr

Clostridium difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from the bacterium most commonly affects older adults in hospitals or in long term care facilities and typically occurs after use of antibiotic medications.

In recent years, Clostridium difficile infections have become more frequent, more severe and more difficult to treat. Each year, tens of thousands of people in the United States get sick from the bacterium, including some otherwise healthy people who aren’t hospitalized or taking antibiotics.

I’m Lynn Lumpkin with CRWE Newswire — Today’s company highlight is Optimer Pharmaceuticals Incorporated trading with the symbol OPTR

Optimer Pharmaceuticals is focused on discovering, developing, and commercializing innovative hospital specialty products that have a positive impact on society. The company focus on medicines that make a significant difference in the lives of patients and reduce the burden of disease.

Fidaxomicin, Optimer Pharmaceuticals’ lead product candidate, is a new antibiotic with a novel mechanism of action being developed for the treatment of Clostridium difficile infection or CDI, the most common nosocomial, or hospital acquired, diarrhea.

According to the Centers for Disease Control and Prevention, the bacterium sickens about 500,000 people a year in the U.S. and kills about 30,000

A Food and Drug Administration advisory panel will evaluate data on the oral drug, fidaxomicin. The medicine would be Optimer’s first product to reach the market if the FDA gives its approval.

Optimer’s Fidaxomicin is the first in a new class of antibiotics that kill harmful bacteria by inhibiting an enzyme known as RNA polymerase without weakening the normal intestinal flora

George Farmer, an analyst at Canaccord Adams Inc. in New York, said, anticipating a favorable response from the FDA, that Sales of the drug may reach $250 million by 2016.

For more information about Optimer Pharmaceuticals Incorporated, symbol OPTR, visit www.optimerpharma.com

I’m Lynn Lumpkin with CRWE Newswire

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.


 
Share/Bookmark
 

Category: Stock Market Videos

Tags: , , , , , , , , , , ,

 
 
 

  • CRWE Network




  •